SeekingAlpha · Aug 19, 2026
Travere Therapeutics: Valuation Suggests A Buy
Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read more about the TVTX stock.
TV
NASDAQ · TVTX
Travere Therapeutics, Inc.
Healthcare · Biotechnology
$62.76
Down-$1.98 (-3.06%)
Updated Sep 20, 2026, 8:04 AM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.13B
- P/E ratio
- -35.27
- Dividend yield
- 0.00%
- 52-week range
- $22.06 – $68.73
- Volume
- 2.24M
- Avg. volume
- 1.89M
Price performance
TVTX price history
1M range · 19 trading sessions · Daily adjusted prices
TVTX closed at $62.76 after 19 trading sessions, down 3.77% for the selected period.
- Last close
- $62.76
- Period change
- -3.77%
- Period low
- $62.51
- Period high
- $67.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $64.89 | $64.89 | $62.47 | $62.76 | 2.24M |
| Sep 17, 2026 | $64.51 | $65.86 | $63.84 | $64.74 | 1.38M |
| Sep 16, 2026 | $62.58 | $64.07 | $62.41 | $63.48 | 2.22M |
| Sep 15, 2026 | $65.31 | $65.32 | $61.40 | $62.51 | 2.1M |
| Sep 14, 2026 | $66.17 | $67.88 | $65.39 | $65.79 | 924.72K |
| Sep 11, 2026 | $67.76 | $68.73 | $66.11 | $66.17 | 1.15M |
| Sep 10, 2026 | $65.60 | $68.59 | $64.4466 | $67.51 | 1.56M |
| Sep 9, 2026 | $65.80 | $68.23 | $65.59 | $66.22 | 1.24M |
| Sep 8, 2026 | $63.86 | $66.535 | $63.48 | $66.07 | 1.36M |
| Sep 4, 2026 | $66.04 | $67.105 | $65.04 | $65.28 | 1.05M |
| Sep 3, 2026 | $67.18 | $68.03 | $66.04 | $66.54 | 1.11M |
| Sep 2, 2026 | $66.37 | $67.82 | $65.76 | $67.23 | 1.09M |
| Sep 1, 2026 | $66.00 | $66.60 | $65.37 | $65.71 | 1.07M |
| Aug 31, 2026 | $65.70 | $66.70 | $65.07 | $66.28 | 1.89M |
| Aug 28, 2026 | $67.27 | $67.45 | $65.37 | $65.67 | 808.52K |
| Aug 27, 2026 | $66.69 | $67.85 | $65.65 | $67.52 | 911.64K |
| Aug 26, 2026 | $66.91 | $67.50 | $65.22 | $67.12 | 1.22M |
| Aug 25, 2026 | $65.74 | $67.34 | $65.74 | $67.01 | 1.51M |
| Aug 24, 2026 | $65.78 | $65.795 | $63.71 | $65.22 | 1.04M |
Latest TVTX news
The latest Smart Investors Daily articles mentioning TVTX.
Stock researchCompany · Overview
TVTX research
Overview
Company profile and research snapshot.
Company profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | Canaccord Genuity | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
ChartMill · Jul 28, 2026
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen
Travere Therapeutics (TVTX) scores perfect 10/10 on technical and setup ratings, forming a bull flag pattern near resistance—ideal breakout candidate.
ChartMill · Jul 25, 2026
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup
A stock screening method identifies breakout candidates with strong earnings momentum and technical setups. Travere Therapeutics (TVTX) scores high with a High Growth Momentum Rating of 6, perfect Technical Rating 10, and Setup Rating 8.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
